CompletedNCT00328978
Quetiapine 800 mg or higher for schizophrenia not responding to treatment
About this title
Read the official source — NCT00328978Medication studyAges 18–65Canada
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Calgary and 16 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateOctober 2003
- Recruitment status
- Completed
- Enrollment listed in the registry
- 330
- Sponsor
- AstraZeneca
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Canada
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00328978
- Official title
Show the full official title
A Canadian, Multicenter, Double-Blind, Randomized, Parallel-Group Study of the Safety, Tolerability, and Efficacy of Treatment With Higher Doses of Quetiapine Fumarate (Seroquel®) Greater Than 800 mg/Day in Schizophrenic or Schizoaffective Subjects.
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Calgary · Edmonton · West Claresholm
14 more locations
- Victoria
- White Rock
- Winnipeg
- Sydney
- Kingston
- London
- Markham
- Mississauga
- Ottawa
- Windsor
- Montreal
- Québec
- Verdun
- Saskatoon
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is AstraZeneca.
Did this study involve medication?
Yes. The study involved medication, including Quetiapine.
Who was this study for?
Listed age limits: 18 years to 65 years.
